The Vadodara-based drugmaker expects 40% US growth in FY27 despite the end of Bosutinib exclusivity this month. According to reports from Business Standard, the US formulations business grew 77% in the September quarter, with the base business contributing 23% growth and new launches accounting for the remainder. Bosutinib, an oncology drug, was described as a 'standout contributor' but its exclusivity period has now concluded. To sustain growth, Alembic plans approximately 30 US drug launches with about 25% carrying New Chemical Entity minus one (NCE-1) shared exclusivity or first-to-file status.
To reduce reliance on commoditised generics, Alembic is reallocating research and development resources towards complex therapeutics including injectables, oncology, and Day-1 and NCE-1 filings. As reported by Business Standard, the company recently signed an agreement with DifGen to in-license approximately 20 complex products, including injectables and transdermal patches. The company has also filed an NCE-1 application in the US for tirzepatide and has semaglutide ready for India, though it is waiting for channel stock and competition to settle.
Alembic's domestic India business grew 14% during the September quarter, while the active pharmaceutical ingredient segment jumped 39%, boosted by contract manufacturing deals. According to reports from Business Standard, growth in rest-of-world markets came in at 12%, which Amin admitted was below expectations, though he projected full-year international growth to recover to the mid-teens. The company ranks 20th to 22nd in India's pharma industry and is targeting market-rate, low-teens growth in FY27 to match the Indian pharmaceutical market. Amin noted that the company has lagged the Indian pharmaceutical market for three to four years and the goal is simply to match it.
Chronic therapies now comprise 55% of Alembic's portfolio and grew faster than the market last quarter, led by cardiac, gynaecology, ophthalmic and diabetes products. As reported by Business Standard, by contrast, acute therapies including anti-infectives and cough-and-cold products lagged. The company is not expanding its field staff currently and is focusing on productivity from existing representatives. Amin indicated there are no external risks for the second half, stating it's more about working on and strengthening the company's position. He noted that a higher ranking in India's pharma industry depends on acquisitions and on how peers grow.
Freight, fuel, and solvent costs have risen amid tensions in West Asia, according to Amin, though rupee depreciation has so far offset much of the pressure. Capital expenditure guidance remains steady at approximately ₹400 crore. The company has missed the first wave of international semaglutide patent expiries in markets such as Canada and Brazil, but is now targeting Europe for this opportunity.
